Interleukin-25 targeting monoclonal antibody - NovaRock Biotherapeutics
Alternative Names: Anti-IL25 monoclonal antibody; IL25 targeting monoclonal antibodyLatest Information Update: 11 Mar 2024
Price :
$50 *
At a glance
- Originator NovaRock Biotherapeutics
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Interleukin 17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Asthma; Atopic dermatitis
Most Recent Events
- 19 Feb 2024 Early research in Asthma in USA (Parenteral) (prior to February 2024 (NovaRock Biotherapeutics pipeline, February 2024)
- 19 Feb 2024 Early research in Atopic dermatitis in USA (Parenteral) prior to February 2024 (NovaRock Biotherapeutics pipeline, February 2024)